Purespring raises 拢80m to target kidney disease
Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has raised 拢80 million in Series B financing. Listed firm Syncona committed 拢19.9m as part of a syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion and British Patient Capital. Syncona founded Purespring in 2020 as one of the … Continue reading Purespring raises 拢80m to target kidney disease
